Previous 10 | Next 10 |
home / stock / amam / amam articles
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million pri...
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. SciSparc recently rega...
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. Ne...
Gainers LQR House Inc. (NASDAQ: LQR) shares surged 109% to $0.3602 in pre-market trading after the company delivered inaugural order to Costco, se...
Newly published abstract regarding dose escalation patients provides key updates including: ?50% PSA reduction observed across putative therape...
U.S. stocks traded mixed, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s sessi...
SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the "Company") (NASDAQ:AMAM), today announced that it will host an...
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence...
Morgan Stanley Fireside Chat Replay Now Available SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the "Company")...
News, Short Squeeze, Breakout and More Instantly...
Ambrx Biopharma Inc. American Depositary Shares (each representing seven) Company Name:
AMAM Stock Symbol:
NYSE Market:
Ambrx Biopharma Inc. American Depositary Shares (each representing seven) Website:
Shandong Weigao Group Medical Polymer Co. Ltd. - Class H (SHWGF) is expected to report for Q4 2023 Country Garden Holdings Co., Ltd. ADR (CTRYY) is expected to report for Q4 2023 Mondi Plc ADR (New) (MONDY) is expected to report for Q4 2023 Telecom Italia S.p.A. ADR - Preference Share...
Ambrx Biopharma Inc. (AMAM) is expected to report $-0.41 for Q4 2023
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Spe...